POTENTIAL PARTNER INFO
Over the next decade, we expect the diagnostic industry to assume an increased level of importance in the delivery of health care. The advent of new drug therapies for viral hepatitis and other liver diseases, and advanced therapeutics, such as liver transplantation, emphasizes the need for diagnostics testing to identify patients "at risk" of deterioration and "in need" of appropriate interventions. Diagnostic tests will increasingly be looked at as the gatekeeper to determine who will best benefit from these treatments.
Research on diseases and new disease makers will drive the emergence of new, high-value diagnostics that have the potential to change the industry significantly. These high-value diagnostic tests can have market opportunities on par with pharmaceuticals.
Why HepQuant?
- HepQuant’s tests may have significant clinical and economic advantages over current or emerging tests on the market.
- HepQuant-STAT™ may identify patients with hepatic impairment who are at early stages of disease. Early detection could lead to effective interventions that could save lives.
- HepQuant -SHUNT™ and HepQuant-FLOW™ tests could fill the need for accurate, specific, sensitive, safe, and non-invasive testing to assess the severity of chronic liver disease and guide disease management.
Information for Potential Partners
HepQuant welcomes discussions about collaborative opportunities including those related to product licensing and acquisition, project funding, and product development.
For further information or to discuss specific opportunities, please
contact us.
